S6.5.1 – Roundtable: FGF-21s and A Promising Future on Cirrhosis

by fisherdev@fisherdigital.com.au | May 12, 2025 | Uncategorized

This conversation is the opening segment of SurfingMASH’s April discussion of drug development in memory of Stephen A. Harrison. In addition to co-hosts Jörn Schattenberg, Louise Campbell and Roger Green, panelists include hepatologists and key opinion leaders Sven...

S6.5 – Drug Development Week: FGF-21s, Cirrhosis, Resmiterom, Gene Therapies

by fisherdev@fisherdigital.com.au | May 12, 2025 | Uncategorized

00:00:00 – Surf’s Up: Season 6 Episode 5 Host Roger Green briefly describes this episode’s three sections and introduces Roundtable guests. The Roundtable panel shares groundbreakers. 00:00:00 – Surf’s Up: Season 6 Episode 5 00:10:39 – Roundtable: A Deep Dive Into...

S6.4.2 – Newsmaker: Fatty Liver Alliance Founder Mike Betel Discusses the Increased Visibility of Patient Advocates

by fisherdev@fisherdigital.com.au | May 12, 2025 | Uncategorized

This week’s Newsmaker is Mike Betel, Founder of the Fatty Liver Alliance. He discusses some of the reasons that key MASLD Patient Advocates like himself are getting more visibility at a broader swath of global conferences and the messages he delivers at the...

S6.4.1 – MASLD Drugs, SLD Spectrum Insights Suggest Bright Future

by fisherdev@fisherdigital.com.au | May 12, 2025 | Uncategorized

Surfing the MASH Tsunami concludes its coverage of the AASLD Emerging Trends Conference on MASLD, MetALD and ALD. This week, the panelists focus on pivotal messages that attendees took away from the conference and what messages they would like to share with listeners....

S6.4 – Reasons for Optimism in MASLD Drug Development and Patient Advocacy

by fisherdev@fisherdigital.com.au | May 12, 2025 | Uncategorized

Surfing the MASH Tsunami concludes its coverage of the AASLD Emerging Trends Conference on MASLD, MetALD and ALD. This week, the panelists focus on pivotal messages that attendees took away from the conference and what messages they would like to share with listeners....

S6.3.3 – Expert: GLI’s Jeff McIntyre discusses implications of FDA job cuts on MASH Drugs

by fisherdev@fisherdigital.com.au | May 12, 2025 | Uncategorized

This week’s Expert is Jeff McIntyre, Vice President, Liver Programs at the Global Liver Institute. His major topic is how recent high-level FDA job cuts might affect MASH drug and diagnostics development. He also shares reactions to FibroSIGHT, HistoIndex’s new...